

# **ම**

### Figures and figure supplements

Adult-born granule cells modulate CA2 network activity during retrieval of developmental memories of the mother

Blake J Laham et al.



**Figure 1.** Adult-born granule cells support retrieval of developmental remote memories of the mother. (**a-aiii**) Confocal images of dentate gyrus granule cells, both mature (ZnT3+) and adult-born (3R-Tau+), and their robust projections to CA2. Confocal images of adult-born granule cell (abGC) 3R-Tau+axons (arrows) (**b**) near proximal dendrite of a CA2 PCP4 + pyramidal cell and (**c**) near proximal dendrite of a CA2 mCherry + PV+ interneuron. (**d**) abGC fibers (3R-Tau+) in the CA2 are more abundant near proximal dendrites (n=7; paired t-test:  $t_6$ =3.163, p=0.0195) of PV + interneurons (mCherry+) than those of pyramidal cells (PCP4+). (**e**) Timeline for behavioral experiment. (**f**) Schematic demonstrating direct social interaction assay used at three experimental time points. (**g**) Ablation of abGCs abolishes difference in investigation time between mother and novel mother (CD1: n=17; TK: n=14; two-way RM ANOVA: Genotype x Drug:  $F_{2,58}$  = 5.352, p=0.0074; Šídák's test p=0.0021). After removing valganciclovir (VGCV) from rodent chow and allowing adult neurogenesis to recover over the course of 6 weeks, mice were able to discriminate between mother and novel mother again (p>0.999). (**h-hii**) Confocal images of abGCs in the DG at three different drug time points. VGCV administration produces a dramatic loss of (**h-hii**) abGCs (3R-Tau + cells) in DG (VGCV: n=8; VGCV+: n=8; unpaired t-test:  $t_{14}$ =6.588, p<0.0001) and (**i-iii**) 3R-Tau+ fibers in CA2 (VGCV: n=8; VGCV+: n=8; unpaired t-test:  $t_{14}$ =0.488, p=0.0036). 6 weeks after removing VGCV from the rodent chow, DG abGC number (**j**, **k**) undergoes a 70% recovery (CD1: n=8; TK: n=8; unpaired t-test:  $t_{14}$ =0.7271, p=0.4791). \*p<0.05, bars represent mean + SEM. Scale bars = 200 µm for **a**, **h**, **i**; 2 µm for **b**, **c**. ns = not significant.

© 2024, BioRender Inc. Figure 1f was created using BioRender, and is published under a CC BY-NC-ND 4.0. Further reproductions must adhere to the terms of this license



**Figure 1—figure supplement 1.** Total investigation times during social interaction. (a) Total investigation times of the mother and a novel mother were assessed for CD1 and GFAP-TK mice before (VGCV-), during (VGCV+), and after valganciclovir (VGCV) administration (VGCV- Recovery) (CD1: n=17; TK: n=14; RM ANOVA: Genotype x Drug:  $F_{6,116} = 1.672$ , p=0.1339; Drug:  $F_{1.173} = 5.515$ , p=0.0072). (b) Total investigation times of the mother and a novel mother were quantified for Nestin-cre mice and Nestin-cre:Gi mice with a 4–6-week-old population of inhibitory DREADD + adult-born granule cells (abGCs) (Nestin-cre: n=31; Nestin-cre:Gi: n=33; Mixed-effects ANOVA: Genotype x Drug x Stimulus:  $F_{1.56} = 4.290$ , p=0.0430; Tukey's test: Nestin-cre Veh Mother vs Novel p=0.0004, Nestin-cre CNO Mother vs Novel p=0.0274, Nestin-cre:Gi Veh Mother vs Novel p=0.0326, Nestin-cre:Gi mice with a 10–12-week-old population of inhibitory DREADD + abGCs (Nestin-cre: n=21; Nestin-cre:Gi: n=17; Mixed-effects ANOVA: Genotype x Drug x Stimulus:  $F_{1.12} = 1.204$ , p=0.2941; Drug:  $F_{1.40} = 60.46$ , p<0.0001). Bars represent mean + SEM. This figure contains data that relates to both main *Figures 1 and 2*.



**Figure 1—figure supplement 2.** Valganciclovir (VGCV) or clozapine-N-oxide (CNO) administration does not alter locomotion. (a) GFAP-TK mice display normal locomotion during social interaction after 6 weeks of VGCV administration (CD1: n=17; TK: n=14; three-way ANOVA: Genotype x Drug x Stimulus:  $F_{1,29} = 0.01998$ , p=0.8886). CNO administration has no effect on locomotion during (b) baseline (Nestin-cre: n=7; Nestin-cre:Gi: n=9; two-way RM ANOVA: Genotype x Drug:  $F_{1,14} = 0.02291$ , p=0.8818) or (c) social stimulus trials (Nestin-cre: n=7; Nestin-cre:Gi: n=9; three-way ANOVA: Genotype x Drug x Stimulus:  $F_{1,14} = 0.06126$ , p=0.8081) in Nestin-cre and Nestin-cre:Gi mice. A significant two-way interaction was observed during social trials, but all post hoc tests failed to reach significance (two-way ANOVA: Genotype x Drug:  $F_{1,14} = 7.180$ , p=0.0180). Bars represent mean + SEM. ns = not significant. This figure contains data that relates to both main *Figures 1 and 2*.



**Figure 2.** Inhibiting 4–6-week-old abGC projections to CA2 prevents discrimination between mothers and novel mothers. (a) Schematic of breeding to produce Nestin-cre:Gi double transgenic offspring. (b) Timeline outlining tamoxifen administration, cannula implantation, and behavioral testing. (c) Schematic demonstrating direct social interaction testing. (d-dii) Confocal images depicting 4–6-week-old Gi-DREADD + abGCs in the DG. (e) Inhibiting 4–6-week-old adult-born granule cell (abGC) projections to CA2 with clozapine-N-oxide (CNO) prevents discrimination between mother and novel mother (Nestin-cre: n=31; Nestin-cre:Gi: n = 33; two-way RM ANOVA: Genotype x Drug:  $F_{1,62} = 4.042$ , p=0.0487; Šídák's test p=0.0057). (f) Inhibiting 10–12-week old abGC projections to CA2 does not influence discrimination between mother and novel mother Nestin-cre: n=21 (Veh), n=17 *Figure 2 continued on next page* 

Laham et al. eLife 2023;12:RP90600. DOI: https://doi.org/10.7554/eLife.90600



#### Figure 2 continued

(CNO); Nestin-cre:Gi: n=18 (Veh), n=15 (CNO); Mixed-effects ANOVA: Genotype x Drug:<sub>1,67</sub> = 1.669, Pp=0.2008. (g) Schematic for experiment assessing abGC contributions to social memory consolidation. (h) Systemic inhibition of abGCs during memory consolidation has no significant effect on social memory (Nestin-cre: n=21; Nestin-cre:Gi: n=18; two-way RM ANOVA: Genotype x Drug:  $F_{1,37}$  = 1.238, p=0.2730). \*p<0.05, bars represent mean + SEM. ns = not significant. Scale bars in d=200 µm.

© 2024, BioRender Inc. Figure 2a, c and g were created using BioRender, and is published under a CC BY-NC-ND 4.0. Further reproductions must adhere to the terms of this license

eLife Short report



**Figure 3.** Adult-born neurons influence CA2 sharp wave ripple (SWR) changes associated with discrimination between novel mother and mother. (a) Timeline of experiment demonstrating tamoxifen injection schedule and electrode implantation in CA2. (b) Confocal image demonstrating accuracy of electrode placement. (c) Example of SWR trace and (d) filtered trace recorded from CA2. (e) CA2 SWR frequency is increased during social interactions, regardless of whether the stimulus is the novel mother or mother (Veh: n=14; CNO: n=14; 2-way RM ANOVA: Stimulus:  $F_{1,13} = 46.40$ , p<0.0001). (f) Inhibiting 4–6-weekold adult-born granule cells (abGCs) with clozapine-N-oxide (CNO) prevents characteristic SWR production patterns present during exposure to novel mothers vs mothers (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,110} = 18.6529$ , p<0.0001; *Figure 3 continued on next page* 

Laham et al. eLife 2023;12:RP90600. DOI: https://doi.org/10.7554/eLife.90600



#### Figure 3 continued

Tukey's test p<0.0001). (g) Inhibiting 4–6-week old abGCs significantly reduces social trial SWR production (Nestin-cre: n=7; Nestin-cre:Gi; n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,228} = 16.2465$ , *P*<0.0001; Tukey's test p=0.0018). (h) Inhibiting 4–6 week old abGCs increases SWR peak amplitude during social interaction trials (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,238} = 3.69$ , p=0.0559) and (j) baseline (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,237} = 6.0322$ , p=0.01477; Tukey's test p=0.0133). (i) Changes in baseline SWR production did not reach significance (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,238} = 3.5101$ , p=0.0622). (k) At the 10–12 week abGC time point, CA2 SWR frequency is increased during social interactions, regardless of stimulus (Veh: n=9; CNO: n=11; Mixed-effects ANOVA: Stimulus:  $F_{1,10} = 133.1$ , p<0.0001). (l) Inhibiting 10–12-week old abGCs has no influence on characteristic SWR production patterns present during exposure to the novel mother vs mother (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=7 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,170} = 0.4496$ , p=0.503), or (o) during baseline recording (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,170} = 0.4496$ , p=0.503), or (o) during baseline recording (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,170} = 2.0552$ , p=0.15352). (n) Inhibiting 10–12-week old adult-born granule cells (abGCs) has no influence on SWR peak amplitude social interaction trials (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,170} = 0.3250$ ) or (p) during baseline (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,170} = 0.3250$ ) or (p) during baseline (Nes

© 2024, BioRender Inc. Figure 3a was created using BioRender, and is published under a CC BY-NC-ND 4.0. Further reproductions must adhere to the terms of this license



**Figure 3—figure supplement 1.** 4–6-week-old a adult-born granule cells (bGCs) influence multiple features of CA2 sharp wave ripples (SWRs). (a) Schematic of electrophysiological recordings during baseline and social trials during the 4–6-week-old abGC timepoint. (b) Silencing 4–6-week old abGCs reduces average CA2 SWR integral (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,236} = 12.83$ , p=0.0004017; Tukey's test p=0.0099). (c) Silencing 4–6-week old abGCs reduces average CA2 SWR duration (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,223} = 24.077$ , p<0.0001; Tukey's test p<0.0001). (d) Silencing 10–12-week old abGCs has no effect on average CA2 SWR integral but a significant interaction is observed (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh and CNO); Mixed-effects ANOVA: Genotype

Figure 3—figure supplement 1 continued on next page

### eLife Short report

#### Figure 3—figure supplement 1 continued

x Drug:  $F_{1,172}$  = 4.0061, p=0.0469; Tukey's test p=0.7457). (e) Silencing 10–12-week old abGCs does not reduce average CA2 SWR duration but a significant interaction is observed (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1172}$  = 8.5609, p=0.003898; Tukey's test p=0.1439). \*p<0.05, bars represent mean + SEM. ns = not significant.

© 2024, BioRender Inc. Figure 3—figure supplement 1a was created using BioRender, and is published under a CC BY-NC-ND 4.0. Further reproductions must adhere to the terms of this license

eLife Short report



**Figure 3—figure supplement 2.** Normalized sharp wave ripple (SWR) generation. (**a**) Silencing 4–6-week-old adult-born granule cells (bGCs) alters CA2 SWR generation (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug x Stimulus:  $F_{1,234} = 13.3621$ , p=0.000317; Tukey's test: Nestin-cre Veh Mother vs Novel p=0.0042, Nestin-cre CNO Mother vs Novel p< 0.0001, Nestin-cre:Gi Veh Mother vs Novel p=0.0003, Nestin-cre:Gi CNO Mother vs Novel p=0.7190). (**b**) Silencing 10–12 week-old abGCs has no influence on CA2 SWR generation (Nestin-cre: n=5; Nestin-cre:Gi: n=7; Mixed-effects ANOVA: Genotype x Drug x Stimulus:  $F_{1,161} = 2.1093$ , p=0.14834; Stimulus:  $F_{1,161} = 33.0013$ , p<0.0001). \*p<0.05, bars represent mean + SEM.

eLife Short report

Neuroscience



**Figure 3—figure supplement 3.** Nonsocial stimuli suppress CA2 sharp wave ripple (SWR) frequency. (a) Schematic of electrophysiological recordings during baseline and exposure to nonsocial object (plastic toy animal) trials during the 4–6-week old abGC timepoint. (b) Nonsocial stimuli slightly inhibit CA2 SWR frequency (Veh: n=14; CNO: n=16; 2-way RM ANOVA: Stimulus:  $F_{1,28} = 7.760$ , p=0.0095). (c) Silencing 4–6-week old adult-born granule cells (abGCs) has no influence on CA2 SWR frequency during object exposure (Nestin-cre: n=5 (Veh), n=7 (CNO); Nestin-cre:Gi: n=8 (Veh), n=9 (CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,95} = 0.7761$ , p=0.3806), (d) average integral (Nestin-cre: n=5, n=7 (CNO); Nestin-cre:Gi: n=9 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,108} = 0.1653$ , p=0.2027). (e) Silencing 4–6-week old abGCs reduces average SWR duration during object trials (Nestin-cre: n=5 (Veh), n=7 (CNO); Nestin-cre:Gi: n=9 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,108} = 0.1653$ , p=0.2027). (e) Silencing 4–6-week old abGCs reduces average SWR duration during object trials (Nestin-cre: n=5 (Veh), n=7 (CNO); Nestin-cre:Gi: n=9 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,108} = 0.005849$ ; Tukey's test p=0.0094). (f) Silencing 4–6-week old abGCs has no effect on SWR peak z-score (Nestin-cre: n=5 (Veh), n=7 (CNO); Nestin-cre:Gi: n=9 (Veh and CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,111} = 0.0003$ , p=0.9874). \*p<0.05, bars represent mean + SEM. ns = not significant.

Figure 3—figure supplement 3 continued on next page

## eLife Short report

### Figure 3—figure supplement 3 continued

© 2024, BioRender Inc. Figure 3—figure supplement 3a was created using BioRender, and is published under a CC BY-NC-ND 4.0. Further reproductions must adhere to the terms of this license

eLife Short report



**Figure 4.** Adult-born neurons influence CA2 phase-amplitude coupling (PAC) changes associated with retrieval of developmental memories of the mother. (a) Example trace of raw local field potential (LFP) (black), 4–12 Hz theta oscillation (magenta), and 50–100 Hz gamma oscillation (green). (b,c) Graphs demonstrating mid-gamma amplitude modulation across theta phases in Nestin-cre:Gi mice. (d) Inhibiting 4–6-week old adult-born granule cells (abGCs) abolishes the increase in theta-mid-gamma PAC present during exposure to the mother (Nestin-cre: n=7; Nestin-cre:Gi: n=8; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,103} = 4.6729$ , p=0.03296; Šídák's test p=0.0219). (e,f) Graphs demonstrating mid-gamma amplitude modulation across theta phases in Nestin-cre:Gi mice. (g) Inhibiting 10–12-week old abGCs has no influence on theta-mid-gamma PAC during exposure to the mother (Nestin-cre: n=4 (Veh), n=5 (CNO); Nestin-cre:Gi: n=8 (Veh), n=7 (CNO); Mixed-effects ANOVA: Genotype x Drug:  $F_{1,18} = 0.2616$ , p=0.6153). \*p<0.05, bars represent mean + SEM.



**Figure 4—figure supplement 1.** 4–6-week old adult-born granule cell (abGC) inhibition does not influence theta and gamma power during social interaction. (**a,ai,c,ci,e,ei**) Normalized power spectra graphs (Social stimulus/baseline). (**b**) Silencing 4–6-week old abGCs has no influence on theta power (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed-effects ANOVA: Genotype x Drug:  $F_{1,14} = 0.2303$ , p=0.6387). (**d**) Silencing 4–6-week old abGCs has no influence on low-gamma power (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed effects ANOVA: Genotype x Drug:  $F_{1,14} = 0.7979$ , p=0.3868). (**f**) Silencing 4–6-week old abGCs has no influence on mid-gamma power (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed effects ANOVA: Genotype x Drug:  $F_{1,14} = 0.7979$ , p=0.3868). (**f**) Silencing 4–6-week old abGCs has no influence on mid-gamma power (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed effects ANOVA: Genotype x Drug:  $F_{1,14} = 0.7979$ , p=0.3868). (**f**) Silencing 4–6-week old abGCs has no influence on mid-gamma power (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed effects ANOVA: Genotype x Drug:  $F_{1,14} = 0.7979$ , p=0.3868). (**f**) Silencing 4–6-week old abGCs has no influence on mid-gamma power (Nestin-cre: n=7; Nestin-cre:Gi: n=9; Mixed effects ANOVA: Genotype x Drug:  $F_{1,28} = 0.3702$ , p=0.5478). Bars represent mean + SEM for **a-ai,cci,e-ei**; + SEM for **b,d,e**. ns = not significant.